Investment Highlights
- Unique technologyDisposable Devices instead of a new drug – while having relatively low risk and short device regulatory pathway the market potential is that of a new drug
- Promising clinical results Extensive studies showed positive clinical results on diabetics, more studies are underway
- Real Need for Patients, Physicians and PayersClinical data indicates that the devices can assist patients achieve better glycemic control, reduce complications and overall treatment costs
- Products have CE markClinical study for FDA approval is ongoing while preparing for product launch in Germany, to be expanded later on, to Europe and the US
- Broad patent portfolio with global coverage
- Experienced management team - supported by world class advisory members
- Clear go-to-market path
And, potential collaboration with all diabetes market players